ClinicalTrials.gg
TerminatedNCT00456846Updated Nov 22, 2019Results posted

First Line Therapy for Patients With Metastatic Breast Cancer

A Phase 2 interventional study of ABI-007 in Metastatic Breast Cancer, sponsored by Celgene. Terminated at 14 sites in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-22.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms — 18 open to participants now, 22 under way, 2 of them phase 3. Albumin-Bound Paclitaxel · Breast Neoplasms.

Enrollment
23rd of 108
123 · median 60
Started
2008
with 13 others
Phase 2
67 of 108
9 open now
Registered
19th of 108
by date
Lead sponsor
9 of 108
Celgene

Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, this one is the 23rd largest by enrollment, is one of 14 that started in 2008, is one of 67 in phase 2, and was the 19th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

18 of the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the toxicity and anti-tumor activity of nab-paclitaxel 100mg/m\^2 administered weekly in a 4-week cycle as first line therapy to patients with metastatic breast cancer who received taxanes as part of their adjuvant therapy and patients who did not receive taxanes as part of their adjuvant therapy.

Read the detailed description

This is an open-label, phase II study to determine the toxicity and antitumor activity of ABI-007 100 mg/m2 administered weekly for 3 weeks followed by a rest week (4-week cycle) as first line therapy to patients with metastatic breast cancer in the following 2 cohorts: Patients who have received a taxane as part of their adjuvant therapy, and patients who did not receive a taxane as part of their adjuvant therapy. Patients will be assessed for antitumor response every 8 weeks.

The last subject received study treatment 11DEC2012. The study was terminated on 31 May 2013 via a notification letter to all investigators on 14 May 2013.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • Metastatic Breast Cancer, ABI-007, Abraxane
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females with confirmed adenocarcinoma of the breast.
  • No prior chemotherapy for breast cancer
  • At least 12 months between completion of chemotherapy and the diagnosis of metastatic disease
  • Stage IV disease
  • (must be equal or greater to 2.0 cm using conventional Computed Tomography (CT) or equal or greater to 1.0 cm using spiral CT except for pulmonary lesions that are well documented on conventional CT scan which must be equal or greater than 1.0 cm)
  • At least 4 weeks since radiotherapy, with full recovery. The measurable disease must be completely outside the radiation portal or there must be radiologic or clinical exam proof of progressive disease within the radiation portal
  • At least 4 weeks since major surgery, with full recovery
  • (ECOG) performance status 0-2
  • Age equal or greater to 18
  • Patients has the following blood counts at Baseline:
  • (ANC) equal or greater to 1.5 x 10\^9 cells/L
  • equal or greater to 100 x 10\^9 cells/L
  • (Hgb) equal or greater to 90 grams/L
  • Patients has the following blood chemistry levels at Baseline:
  • (AST) Serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT) serum glutamic:pyruvic transaminase (SGPT)less than or equal to 2.5x (ULN);
  • total normal (unless bilirubin elevation is due to Gilbert's (Disease);
  • alkaline phosphatase less than or equal 2.5x ULN (unless bone metastasis is present in the absence of liver metastasis);
  • Creatinine less than or equal to 1.5mg/dL
  • Current sensory neuropathy Grade 0 or 1 by Breast Cancer Index (BCI) Common Toxicity Criteria Adverse Events ()
  • If female of , pregnancy test is negative (within 72 hours of the first dose of study drug).
  • If fertile, the patient agrees to use an effective method of to avoid pregnancy for the duration of the study
  • Patient is able to supply unstained slides or 1 tumor block of her primary breast tumor or a of a current site of metastasis for Secreted protein acidic and rich in cysteine (SPARC) analysis
  • has been obtained

Exclusion criteria

Exclusion Criteria:

  • Concurrent immunotherapy or hormonal therapy (other than Herceptin) for breast cancer
  • Parenchymal , unless documented to be clinically and radiographically stable for at least 6 months after treatment
  • Serious intercurrent medical or psychiatric illness, including serious active infection
  • History of class II-IV congestive heart failure
  • History of other within the last 5 years which could affect the diagnoses or assessment of breast cancer, with the exception of basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
  • Patients who have received an drug within the previous 3 weeks
  • Patient is currently enrolled in a different clinical study in which investigational procedures are performed or investigational therapies are administered. Also a patient may not enroll in such clinical trials while participating in this study.
  • Pregnant or nursing women
  • Patients with prior to Taxol or Taxotere
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    ABI-007

    100 mg/m\^2 ABI-007 was administered by intravenous (IV) infusion over 30 minutes weekly for 3 weeks followed by 1 week rest. Therapy continued until disease progression or unacceptable toxicity.

    Drug: ABI-007

Interventions

  • 100 mg/m\^2 ABI-007 weekly for 3 weeks followed by 1 week rest

    Also known as: Nab-paclitaxel, Abraxane

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 Based on Investigator and Independent Reviewers

    Overall response rate (ORR) is complete response (CR) + partial response (PR). Complete response (CR): The disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. Disappearance of all non-target lesions. The normalization of tumor marker level confirmed at least 4 weeks after initial documentation. Partial response (PR): At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing. As well as persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits

    Time frame: Every 8 weeks from study start until disease progression; Up to 61 months

Secondary outcomes

  1. Percentage of Participants With Disease Control

    Disease control was defined as stable disease (SD) for ≥ 16 weeks or complete response (CR) or partial response (PR). Response was evaluated by the Investigator and by an independent reviewer using Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.0. See Outcome #1 for definitions of CR and PR. RECIST defines SD for target lesions as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.

    Time frame: Every 8 weeks from study start until disease progression; Up to 61 months

  2. Progression-free Survival (PFS)

    PFS was defined as the time from the first dose of study drug to the start of progression or patient death (any cause), whichever occurred first. Participants who did not have progression or did not die were censored at the last known time the participant was progression free. Participants who initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated.

    Time frame: Study start until disease progression, death, or up to data cut off of 31 May 2013; up to 61 months

  3. Duration of Response Based on Independent Reviewer Assessment

    Duration of response was defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Participants who did not have progression or had not died were censored at the last known time the participant was progression free. Participants who had initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. CR and PR were defined in outcome #1. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST).

    Time frame: Initial response until disease progression; or until data cut off 31 May 2013; up to 61 months

  4. Duration of Response Based on Investigator Assessment

    Duration of response was defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Participants who did not have progression or had not died were censored at the last known time the participant was progression free. Participants who had initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Complete response (CR) and partial response (PR) were defined in outcome #1. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST).

    Time frame: Initial response until disease progression; or until data cut off 31 May 2013; up to 61 months

  5. Patient Survival

    Participant survival was the time from the first dose of study drug to participant death from any cause. Participants who did not die were censored at the last known time the participant was alive.

    Time frame: Study start until death, or until data cut-off 31 May 2013; up to 61 months

  6. Number of Participants Experiencing Dose Reductions, Interruptions, or Dose Delays of Study Drug

    The number of participants with dose reductions, dose interruptions and dose delays that occurred during the treatment period. Dose reductions, interruptions and delays are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.

    Time frame: Day 1 of study drug to Day 940; data cut off 31 May 2013

  7. Number of Participants With Treatment-Emergent Adverse Events

    Count of study participants who had at least one treatment-emergent adverse event (TEAE) defined as any adverse event that began or worsened in grade after the start of study drug through 30 days after the last dose of study drug. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity: severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE. Severity grade 5 = death.

    Time frame: Day 1 to Day 940

07

Results

Posted Jul 18, 2014

Participant flow

Participant flow — Overall Study
MilestoneAbraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)
Started4776
Completed3148
Not completed1628
Withdrew: Adverse event215
Withdrew: Physician decision116
Withdrew: Protocol deviation20
Withdrew: Participant discretion15
Withdrew: Other02

Outcome measures

PrimaryPercentage of Participants With Objective Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 Based on Investigator and Independent Reviewers

Overall response rate (ORR) is complete response (CR) + partial response (PR). Complete response (CR): The disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. Disappearance of all non-target lesions. The normalization of tumor marker level confirmed at least 4 weeks after initial documentation. Partial response (PR): At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing. As well as persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits

Time frame:
Every 8 weeks from study start until disease progression; Up to 61 months
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 Based on Investigator and Independent Reviewers
percentage of participantsAbraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)
Investigator Assessment30 (16.7 to 42.9)28 (17.6 to 37.7)
Independent Reviewer Assessment32 (18.6 to 45.2)32 (21.1 to 42.0)
SecondaryPercentage of Participants With Disease Control

Disease control was defined as stable disease (SD) for ≥ 16 weeks or complete response (CR) or partial response (PR). Response was evaluated by the Investigator and by an independent reviewer using Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.0. See Outcome #1 for definitions of CR and PR. RECIST defines SD for target lesions as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.

Time frame:
Every 8 weeks from study start until disease progression; Up to 61 months
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control
percentage of participantsAbraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)
Investigator Assessment51 (36.8 to 65.4)57 (45.4 to 67.7)
Independent Reviewer Assessment55 (41.1 to 69.5)57 (45.4 to 67.7)
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from the first dose of study drug to the start of progression or patient death (any cause), whichever occurred first. Participants who did not have progression or did not die were censored at the last known time the participant was progression free. Participants who initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated.

Time frame:
Study start until disease progression, death, or up to data cut off of 31 May 2013; up to 61 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsAbraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)
Investigator Assessment6.0 (3.5 to 8.8)6.7 (5.3 to 7.3)
Independent Reviewer Assessment5.3 (3.3 to 7.3)5.3 (3.5 to 6.6)
SecondaryDuration of Response Based on Independent Reviewer Assessment

Duration of response was defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Participants who did not have progression or had not died were censored at the last known time the participant was progression free. Participants who had initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. CR and PR were defined in outcome #1. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST).

Time frame:
Initial response until disease progression; or until data cut off 31 May 2013; up to 61 months
Reported as:
Median · months
Duration of Response Based on Independent Reviewer Assessment
monthsAbraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)
Duration of Response Based on Independent Reviewer Assessment10.9 (7.3 to 18.9)9.2 (7.4 to 14.2)
SecondaryDuration of Response Based on Investigator Assessment

Duration of response was defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Participants who did not have progression or had not died were censored at the last known time the participant was progression free. Participants who had initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Complete response (CR) and partial response (PR) were defined in outcome #1. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST).

Time frame:
Initial response until disease progression; or until data cut off 31 May 2013; up to 61 months
Reported as:
Median · months
Duration of Response Based on Investigator Assessment
monthsAbraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)
Duration of Response Based on Investigator Assessment10.5 (8.8 to 25.4)10.8 (8.7 to 22.4)
SecondaryPatient Survival

Participant survival was the time from the first dose of study drug to participant death from any cause. Participants who did not die were censored at the last known time the participant was alive.

Time frame:
Study start until death, or until data cut-off 31 May 2013; up to 61 months
Reported as:
Median · months
Patient Survival
monthsAbraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)
Patient Survival20.9 (14.3 to 28.0)20.0 (13.8 to 28.6)
SecondaryNumber of Participants Experiencing Dose Reductions, Interruptions, or Dose Delays of Study Drug

The number of participants with dose reductions, dose interruptions and dose delays that occurred during the treatment period. Dose reductions, interruptions and delays are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.

Time frame:
Day 1 of study drug to Day 940; data cut off 31 May 2013
Reported as:
Number · participants
Number of Participants Experiencing Dose Reductions, Interruptions, or Dose Delays of Study Drug
participantsAbraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)
Patients with at Least One Dose Reduction1119
Patients with at Least One Dose Interruption32
Patients with at Least One Dose Delay/Not Given2039
SecondaryNumber of Participants With Treatment-Emergent Adverse Events

Count of study participants who had at least one treatment-emergent adverse event (TEAE) defined as any adverse event that began or worsened in grade after the start of study drug through 30 days after the last dose of study drug. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity: severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE. Severity grade 5 = death.

Time frame:
Day 1 to Day 940
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events
participantsAbraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)
≥1 Adverse Event (AE)4675
≥1 Treatment related Adverse Event4174
≥ 1 Serious Adverse Event514
Treatment related Serious Adverse Event27
≥1 One Grade 3/4 Adverse Event2536
≥1 One Grade 3 or Higher Adverse Event2536
≥1 AE leading to treatment discontinuation216
≥1 AE leading to death02
≥1 AE leading to dose reduction of study drug1118
≥1 AE leading to dose interruption of study drug20
≥1 AE leading to dose delay of study drug1529

Adverse events

Collected over Any Adverse Event (AE) that started after initial study drug administration through the end of the study or 30 days after the last treatment, whichever was later, were followed until the AE had resolved or stabilized. Upt to 61 months.. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abraxane (Prior Taxane Therapy)—5/47 (10.6%)46/47 (97.9%)
Abraxane (No Prior Taxane Therapy)—14/76 (18.4%)75/76 (98.7%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventAbraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)
PneumoniaInfections and infestations0/473/76
Pleural effusionRespiratory, thoracic and mediastinal disorders0/472/76
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/472/76
BacteraemiaInfections and infestations1/470/76
CellulitisInfections and infestations1/470/76
PneumothoraxRespiratory, thoracic and mediastinal disorders1/470/76
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/470/76
Pericardial effusionCardiac disorders1/470/76
DiarrhoeaGastrointestinal disorders1/470/76
Lower gastrointestinal haemorrhageGastrointestinal disorders1/470/76
Most frequent other events
Showing 10 of 83
Most frequent other events
EventAbraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)
AlopeciaSkin and subcutaneous tissue disorders29/4761/76
FatigueGeneral disorders33/4755/76
NauseaGastrointestinal disorders24/4747/76
Peripheral sensory neuropathyNervous system disorders22/4744/76
DiarrhoeaGastrointestinal disorders15/4737/76
Decreased appetiteMetabolism and nutrition disorders16/4730/76
HeadacheNervous system disorders17/4720/76
ConstipationGastrointestinal disorders15/4715/76
MyalgiaMusculoskeletal and connective tissue disorders15/4713/76
Pain in extremityMusculoskeletal and connective tissue disorders14/4715/76

Baseline characteristics

Treated Population

Age, Continuous
Age, Continuous(years)Abraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)Total
Mean55.3 ± 9.7858.3 ± 10.8857.2 ± 10.54
Sex: Female, Male
Sex: Female, Male(Participants)Abraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)Total
Female4776123
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Abraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)Total
Asian055
Black, of African Heritage235
Native Hawaiian or Other Pacific Islander101
White, Non-Hispanic/Non Latino4160101
White, Hispanic or Latino055
Other-Unspecified336
Menopausal Status
Menopausal Status(participants)Abraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)Total
Premenopausal121224
Postmenopausal356499
Stage at Primary Diagnosis
Stage at Primary Diagnosis(participants)Abraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)Total
Stage I41216
Stage IIa71219
Stage IIb141327
Stage IIIa11819
Stage IIIb6410
Stage IIIc5510
Stage IV01919
Unknown033
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Abraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)Total
0 (fully active)213859
1 (restrictive but ambulatory)223052
2 (ambulatory but unable to work)4812
3 (limited self-care) + 4 (completely disabled)000
Physician Assessment of Peripheral Neuropathy] [2]
Physician Assessment of Peripheral Neuropathy] [2](participants)Abraxane (Prior Taxane Therapy)Abraxane (No Prior Taxane Therapy)Total
Grade 03769106
Grade 110717
08

Study locations

14 sites
  • BC Cancer Agency-Burnaby
    Burnaby, British Columbia, Canada
  • Lions Gate Hospital
    North Vancouver, British Columbia, Canada
  • B.C.C.A Vancouver Island Center
    Victoria, British Columbia, Canada
  • Dr. H. Bliss Murphy Cancer Center
    St. Johns, Newfoundland and Labrador, Canada
  • The Royal Victoria Hospital
    Barrie, Ontario, Canada
  • London Regional Cancer Centre
    London, Ontario, Canada
  • Mount Sinai Hospital
    Toronto, Ontario, Canada
  • St. Michael's Hospital
    Toronto, Ontario, Canada
  • Toronto Synnybrook Cancer Centre
    Toronto, Ontario, Canada
  • Windsor Regional Hospital
    Windsor, Ontario, Canada
  • Hospital de la Cite-de-la Sante-de-Laval
    Laval, Quebec, Canada
  • Centre Hospitalier de l'Universite de Montreal-Hotel-Dieu
    Montreal, Quebec, Canada
  • McGill University
    Montreal, Quebec, Canada
  • CHA: Saint Sacrement Hospital
    Quebec, Canada
09

References and documents

Publications

  • Brezden B, et al. An open-label, phase II study of weekly nab-paclitaxel as first-line therapy for patients (pts) with metastatic breast cancer (MBC): Safety update. Presented at 2010 ASCO Annual Meeting, June 4-8, 2010, Chicago, IL. Abstract No 1127 C.
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2008 to primary completion in Dec 2012, 58 months.

Results were first posted in Jul 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2007
First posted
Apr 5, 2007
StartActual
Feb 1, 2008
Primary completionActual
Dec 11, 2012
CompletionActual
May 31, 2013
Results first posted
Jul 18, 2014
Last update
Nov 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00456846
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Apr 5, 2007
Start date
Feb 1, 2008
Primary completion
Dec 11, 2012
Completion
May 31, 2013
Results posted
Jul 18, 2014
Last update
Nov 22, 2019

Study contacts

Sasha Smiljanik, MD
principal investigator · Lions Gate Hospital
Kara Laing, MD
principal investigator · Dr. H. Bliss Murphy Cancer Center
Wendy Lam, MD
principal investigator · BC Cancer Agency-Burnaby
Maureen Trudeau, MD
principal investigator · Toronto Sunnybrook Cancer Centre
Vanessa Bernstein, MD
principal investigator · B.C.C.A. Vancouver Island Center
Jawaid Younus, MD
principal investigator · London Regional Cancer Centre
Lawrence Panasci, MD
principal investigator · McGill University
Guy Cantin, MD
principal investigator · CHA: Saint Sacrement Hospital
Nicolas Raymond, MD
principal investigator · Hospital de la Cite-de-la Sante-de-Laval
Robert El-Maraghi, MD
principal investigator · The Royal Victoria Hospital
Christine Brezden-Masley, MD
principal investigator · Unity Health Toronto
Andre Robidoux, MD
principal investigator · Centre Hospitalier de l'Universite de Montreal-Hotel-Dieu
Martin Blackstein, MD
principal investigator · MOUNT SINAI HOSPITAL
Caroline Hamm, MD
principal investigator · Windsor Regional Cancer Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion